Mr. Gallagher, MBA, CFA, is an accomplished healthcare and capital markets executive and investor with a distinguished record of success in both the public and private markets. He has over 25 years of life-science experience on Wall Street and in industry. Mr. Gallagher serves as Managing Director of Laidlaw Venture Partners and Senior Managing Director and head of healthcare institutional sales at Laidlaw & Co. (UK) Ltd. Pat is CEO of Voltron Therapeutics, which is developing a novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. He also is CEO of PD Theranostics, which is optimizing and standardizing its proprietary prognostic imaging workflows and predictive artificial intelligence (AI) algorithms to enhance existing pathology results and provide predictive data designed to drive clinical decisions. Mr. Gallagher serves as a strategic consultant for Athenex, Inc., a biopharmaceutical firm focused on next-generation therapies in oncology and immunology. He also is treasurer of AerWave Medical and sits on the board of directors at Algorithm Sciences, Cingulate Therapeutics, and Evermore Global Advisors, a global money manager. Mr. Gallagher co-founded BDR Research Group, LLC, an independent sell-side research firm specializing in healthcare investing, financing and operations, and served as its chief executive officer.

Luba is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. She is also the CEO of one of BSC’s portfolio companies Kojin Therapeutics, which is discovering and developing novel therapeutics in oncology, fibrosis, and immune modulation. She is a professor at Harvard University in the School of Engineering and Applied Sciences. Luba has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Luba has led $5B+ in deals and investments across multiple therapeutic areas and life sciences and tech sectors globally. She has also co-founded biotech and digital health companies in the immunotherapy, AI/ML, women's health and microbiome space, including Luca Biologics. She has served on multiple public, private, and non-profit boards, including the Massachusetts Biotechnology Council (MassBio), Kojin Tx, Brooklyn ImmunoTherapeutics, BenchSci, In8Bio, and OS Fund, a SPAC. She has advised leading academic centers globally including the CEO of the Dana-Farber Cancer Institute as well as the Director of the Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. Luba is also a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.

Dr. Azadeh Khanicheh is the President and Co-Founder of EnVision Endoscopy, a medical device startup based in Lowell, MA developing novel devices to address the clinical needs for endoscopic surgeries. EnVision Endoscopy is the recipient of NSF SBIR award, and recently closed a SEED round to advance the development of a novel image guided suturing device for endoscopic procedures. Dr. Khanicheh is one of the inaugural awardees of the MLSC’s Massachusetts Next Generation Initiative (MassNextGen) initiatives and participated in MassCONNECT program. Dr. Khanicheh has over a decade of experience in design, development, and launch of innovative medical devices, and served different technical lead engineering positions at PENTAX Medical, BD Medical, and Helbing Technik. She led multiple innovation programs on different portfolios of medical devices and evaluated new technologies during this period. She has worked very closely with commercial and marketing experts in the medical device industry. The teams she has led in the past have brought several products from conception through to commercial launch. Dr. Khanicheh has a Ph.D. in Mechanical and Biomedical Engineering and developed one of the first fMRI compatible devices during her tenure at Northeastern University and MGH/HST Martinos Center for Biomedical Imaging.

Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs. Dr. O’Day serves on the Personalized Medicine Coalition (PMC) Board of Directors. In this role, Dr. O’Day collaborates with stakeholders across academia, industry, and government to increase access to personalized medicine. Dr. O’Day also supports the next generation of scientists as adjunct faculty at Boston College, where she taught metabolism and entrepreneurship. Dr. O’Day was recognized by Boston Business Journal as a 40 under 40 honoree in 2020. She is also on the Steering Committee and a contributor for Scientific American's annual "Top 10 Emerging Technologies". During her graduate and undergraduate studies, Dr. O’Day received many of the most prestigious research awards for her personal scientific accomplishments. She earned her Ph.D. from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.